MedTrace Logo

Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis

NCT02344719 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-09-25

No results posted yet for this study

Summary

The investigators want to analyze the effect of Taurin on portal hemodynamics in patients with advanced liver cirrhosis.

Conditions

  • Cirrhosis
  • Portal Hypertension

Interventions

DRUG

Taurin 6g per day per oral for 28 days

Taurin 6g per day per oral for 28 days

PROCEDURE

HVPG Measurement baseline

On day 1 (baseline) and day 28 HVPG measurement will be performed

PROCEDURE

HVPG Measurement day 28

On day 1 (baseline) and day 28 HVPG measurement will be performed

DRUG

Placebo 6g per day per oral for 28 days

Placebo to Taurin 6g per day per oral for 28 days

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Arnulf Ferlitsch, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-05-31
Completion
2015-06-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02344719 on ClinicalTrials.gov